Abstract Cushing's disease (CD), or pituitary-dependent Cushing's syndrome, is a severe
endocrine disease caused by a corticotroph pituitary tumor and associated with increased …

Somatostatin, also known as somatotropin-release inhibitory factor, is a cyclopeptide that
exerts potent inhibitory actions on hormone secretion and neuronal excitability. Its …

Objective: The objective is to formulate clinical practice guidelines for treating Cushing's
syndrome. Participants: Participants include an Endocrine Society-appointed Task Force of …

Background Cushing's disease is associated with high morbidity and mortality. Pasireotide,
a potential therapy, has a unique, broad somatostatin-receptor–binding profile, with high …

Somatostatin is a peptide with a potent and broad antisecretory action, which makes it an
invaluable drug target for the pharmacological management of pituitary adenomas and …

Objective: Our objective was to evaluate the published literature and reach a consensus on
the treatment of patients with ACTH-dependent Cushing's syndrome, because there is no …

Pasireotide (SOM230) is a multi-receptor ligand somatostatin analogue with high binding
affinity for somatostatin receptor subtypes sst1, 2, 3 and sst5. Pasireotide potently …

Context: There is currently no medical therapy for Cushing's disease that targets the pituitary
adenoma. Availability of such a medical therapy would be a valuable therapeutic option for …

Somatotropin-release inhibitory factor (SRIF) is a major regulator of pituitary function, mostly
inhibiting hormone secretion and to a lesser extent pituitary cell growth. Five SRIF receptor …

Object The aim of this paper was to demonstrate the long-term results following
microsurgery in a single surgeon's continuous series of patients with Cushing disease (CD) …